These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2441 related articles for article (PubMed ID: 28607485)

  • 21. Exosomal KRAS mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression.
    Shang A; Gu C; Zhou C; Yang Y; Chen C; Zeng B; Wu J; Lu W; Wang W; Sun Z; Li D
    Cell Commun Signal; 2020 Mar; 18(1):52. PubMed ID: 32228650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer.
    Kahlert C; Melo SA; Protopopov A; Tang J; Seth S; Koch M; Zhang J; Weitz J; Chin L; Futreal A; Kalluri R
    J Biol Chem; 2014 Feb; 289(7):3869-75. PubMed ID: 24398677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRAS
    Hobbs GA; Der CJ
    Subcell Biochem; 2022; 98():205-221. PubMed ID: 35378710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
    Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
    Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.
    Yang K; Li Y; Lian G; Lin H; Shang C; Zeng L; Chen S; Li J; Huang C; Huang K; Chen Y
    Int J Cancer; 2018 Jun; 142(11):2323-2334. PubMed ID: 29315556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer.
    Weyandt J
    Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ras and exosome signaling.
    Sexton RE; Mpilla G; Kim S; Philip PA; Azmi AS
    Semin Cancer Biol; 2019 Feb; 54():131-137. PubMed ID: 30769101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer.
    Zeng L; Li J; Wang Y; Qian C; Chen Y; Zhang Q; Wu W; Lin Z; Liang J; Shuai X; Huang K
    Nanomedicine; 2014 Feb; 10(2):463-72. PubMed ID: 24028894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A.
    Tu Q; Hao J; Zhou X; Yan L; Dai H; Sun B; Yang D; An S; Lv L; Jiao B; Chen C; Lai R; Shi P; Zhao X
    Oncogene; 2018 Jan; 37(1):128-138. PubMed ID: 28892048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
    Du Y; Shang BY; Sheng WJ; Zhang SH; Li Y; Miao QF; Zhen YS
    Oncotarget; 2016 Sep; 7(36):58418-58434. PubMed ID: 27517152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47.
    Hu H; Cheng R; Wang Y; Wang X; Wu J; Kong Y; Zhan S; Zhou Z; Zhu H; Yu R; Liang G; Wang Q; Zhu X; Zhang CY; Yin R; Yan C; Chen X
    J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36413402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer.
    Melo SA; Luecke LB; Kahlert C; Fernandez AF; Gammon ST; Kaye J; LeBleu VS; Mittendorf EA; Weitz J; Rahbari N; Reissfelder C; Pilarsky C; Fraga MF; Piwnica-Worms D; Kalluri R
    Nature; 2015 Jul; 523(7559):177-82. PubMed ID: 26106858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.
    Wang QJ; Yu Z; Griffith K; Hanada K; Restifo NP; Yang JC
    Cancer Immunol Res; 2016 Mar; 4(3):204-14. PubMed ID: 26701267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex.
    Rao DD; Luo X; Wang Z; Jay CM; Brunicardi FC; Maltese W; Manning L; Senzer N; Nemunaitis J
    PLoS One; 2018; 13(5):e0193644. PubMed ID: 29851957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm.
    Taki K; Ohmuraya M; Tanji E; Komatsu H; Hashimoto D; Semba K; Araki K; Kawaguchi Y; Baba H; Furukawa T
    Oncogene; 2016 May; 35(18):2407-12. PubMed ID: 26257060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trisomy of the Dscr1 gene suppresses early progression of pancreatic intraepithelial neoplasia driven by oncogenic Kras.
    Lee JC; Shin J; Baek KH
    Biochem Biophys Res Commun; 2013 Oct; 440(1):50-5. PubMed ID: 24041692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An exosome-mimicking membrane hybrid nanoplatform for targeted treatment toward Kras-mutant pancreatic carcinoma.
    Deng L; Zhang H; Zhang Y; Luo S; Du Z; Lin Q; Zhang Z; Zhang L
    Biomater Sci; 2021 Aug; 9(16):5599-5611. PubMed ID: 34250995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 123.